Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06737536 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT06737536 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 100 participants.
The verdict
NCT06737536, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medicine NNC0662-0419 or placebo (a "dummy" medicine without any active ingredients) given by study staff as an injection under participants skin. Which treatment participants will get is decided by chance. NNC0662-0419 is a new medicine, which cannot be prescribed by doctors. This is the first time the medicine is being given to humans. The study will last for about 9 months.
Interventions
- DRUG NNC0662-0419
- OTHER Placebo (NNC0662-0419)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2025-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06737536
The ClinicalTrials.gov registry entry for NCT06737536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC0662-0419 is the first listed.
NCT06737536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06737536 about?
NCT06737536 is a clinical study titled "A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity". This study is testing a new study medicine which may be used to treat people living with overweight or obesity. The purpose of the study is to see if the new study medicine is safe, how it works in human body and what human body does to the study medicine. Participants will either get the study medi...
What is the current status of trial NCT06737536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-12-18. Estimated completion is 2025-07-26.
What interventions are being tested in trial NCT06737536?
The interventions under investigation include: NNC0662-0419 (DRUG), Placebo (NNC0662-0419) (OTHER).
Who is sponsoring clinical trial NCT06737536?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.